KOREA HEALTH INDUSTRY DEVELOPMENT INSTITUTE(KHIDI)
发明人:
AHN, Byeong Woo,안병우,KIM, Young Soo,김영수,JEONG, Heon Sang,정헌상,SHIN, Sang-Kyung,신상경,KIM, Tae-Wang,김태왕,YOUM, So-Young,염소영
申请号：
KRKR2012/000213
公开号：
WO2012/118277A3
申请日:
2012.01.09
申请国别(地区):
WO
年份:
2012
代理人:
摘要：
The present invention relates to a use of quercetin 3-O-β-(2-galloyl)rhamnoside (QGR) as an active ingredient for promoting hematogenesis, treating, preventing or improving cytopenia and treating or improving damaged bone marrow. QGR, an active ingredient of the present invention, concentration-dependently increases the expression of cytokine stem cell factor (SCF), granulocyte-macrophage colony stimulating factor (GM-CSF) and erythropoietin (Epo) associated with hematogenesis in bone marrow stromal cells, promotes burst forming unit-erythroid (BFU-E) formations, and promotes the generation of TER-119-positive cells, which are an erythrocyte-based cells. In addition, the QGR promotes the formation of erythrocytes, leucocytes, blood platelets and hemoglobin, promotes the formation of hematopoietic stem/progenitor cells and mesenchymal stem/progenitor cells and the differentiation of a CFU-F, which is an early cell in differentiation of mesenchymal stem cells, and promotes the recovery of bone marrow tissues through the formation of megakaryocytes around the blood vessels of damaged bone marrow tissues, the formation of osteoids and the recovery of damaged vessel endothelial cells. QGR, an active ingredient of the present invention, can be very useful for promoting blood corpuscle formation, treating cytopenia and treating damaged bone marrow.La présente invention concerne lutilisation de quercétine 3-O-β-(2-galloyl)rhamnoside (QGR) comme ingrédient actif pour activer lhématogenèse, traiter, prévenir ou améliorer la cytopénie et traiter ou améliorer une moelle osseuse endommagée. Le QGR, un ingrédient actif selon la présente invention, augmente en fonction de la concentration lexpression du facteur des cellules souches (SCF) cytokine, du facteur stimulant les colonies de granulocytes-macrophages (GM-CSF) et de lérythropoïétine (Epo) associés à lhématogenèse dans les cellules stromales de la moelle osseuse, active les formations de cellules précurseurs des érythrocytes
